Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
about
The Role of PARP Inhibitors in the Treatment of Gynecologic MalignanciesImplementing an integrated health protection/health promotion intervention in the hospital setting: lessons learned from the Be Well, Work Well studyPoly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancerMechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancerConcordant and opposite roles of DNA-PK and the "facilitator of chromatin transcription" (FACT) in DNA repair, apoptosis and necrosis after cisplatinFailure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitroComprehensive molecular portraits of human breast tumoursBRCAness: finding the Achilles heel in ovarian cancerProteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancerCytotoxic and targeted therapy for hereditary cancersManagement of relapsed ovarian cancer: a reviewThe biological effects and clinical implications of BRCA mutations: where do we go from here?Trial watch - inhibiting PARP enzymes for anticancer therapyProfile of olaparib in the treatment of advanced ovarian cancerTargeted agents in epithelial ovarian cancer: review on emerging therapies and future developmentsRole of Biomarkers in the Development of PARP InhibitorsPARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future PerspectivesDNA repair targeted therapy: The past or future of cancer treatment?DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerSuccesses and Challenges of PARP Inhibitors in Cancer TherapyTargeted Therapies in Triple-Negative Breast CancerOvarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a ChallengeHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerOlaparib in the management of ovarian cancerPARP inhibitors in the management of breast cancer: current data and future prospectsRole of mesenchymal cells in the natural history of ovarian cancer: a reviewPredictive biomarkers in precision medicine and drug development against lung cancerPatient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatmentNovel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibitionBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsRINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesisGenetics of the serrated pathway to colorectal cancerThe Valley of Death in anticancer drug development: a reassessmentChemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promisingSynthetic lethality and cancer: cohesin and PARP at the replication forkAdvances in using PARP inhibitors to treat cancerGenomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersThe role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapyTargeting DNA damage response in cancer therapyPARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
P2860
Q21129302-403E6F36-2E70-4C12-B5FE-F321E93F5949Q23913188-4A791B33-4636-4CD2-B858-BA7E7489B8ECQ24187899-E7293FC0-91EF-445F-BB68-8C6CBE254157Q24302687-FA04CDA5-52CE-4725-A5F6-A13E363DA51EQ24306623-236D6FA6-6309-46A6-8BCA-1FB5963CD605Q24615499-F61BFEE6-07FA-417D-80DE-D164EE286CF7Q24630844-894CC66C-3317-47D4-9FDD-B25CBC7AD848Q24630872-F1ECB828-95DC-445C-9DB6-5D56632A8EA9Q24632628-71054A66-F612-4E54-A733-E525FCA844E1Q26739366-33BD7086-0457-455A-8BE4-275844D3A30CQ26741755-4B1D4205-64FA-4174-84C2-969D324AE17AQ26741851-BC0CBD26-7F32-484E-8CFD-0EB87659F57FQ26745673-9450CA7F-9BD2-40B7-A496-996914E5F274Q26749284-F3C86662-B67F-412B-9C18-64266D022085Q26750649-09494D8A-8161-4EDF-9E2A-5B5AA4E96F66Q26753159-B86FE517-6CA6-4F70-A50F-559E2BAB45BEQ26768661-11AD503E-4218-4401-9DC3-87FF434D55EEQ26768679-BC5F272F-63EA-4075-B29E-0326952B720BQ26776513-AC05E88F-977C-4D08-BFF8-7D328D0F3AAFQ26777131-FCC5E101-E075-48F2-AE43-9BC6ABA74C1BQ26777736-6ABF8200-9065-49C3-8D3D-5D00E5584633Q26777846-C190F006-5822-447A-8CC1-A7F8CD8E00F1Q26783551-1E1EE41B-AC9B-4E9E-8B62-1935A2FBC5F6Q26797166-C1028C37-5811-4D1D-A9D1-375A6D15C0F6Q26798352-1C06EB3B-AA7B-4DDE-9BA3-6DD791C796A2Q26823555-E4FC7F59-FCCA-4BF6-8396-B3D82ECB83D5Q26824536-4A101CA3-F59A-40A6-A740-DB2E2DEE54DBQ26829125-3288184F-95D8-417F-B7D7-51FB29D3BA05Q26851765-DC0E7528-573B-4DC5-9EE5-9C127071EA9EQ26852274-7A5AB64D-7088-4B20-894F-0D49BDECBF77Q26853207-89F23739-CB13-4F2A-A7BD-09EE77E13222Q26860993-1FEC5A7C-213B-440E-A960-E177F658A6C6Q26861274-CF210F58-C98C-4746-B842-7E73E6CA1B84Q26863501-4DE85CC5-43F8-40DE-BC40-6EEBF5B6A079Q26991603-98205E58-C960-42B9-87B2-6D08FFDDD7F3Q27003972-D8361441-913F-4CAD-B65F-CBDBA0FF0A26Q27006938-D8F9430C-E365-49D6-8386-069639529787Q27010084-1572CD6D-1872-44EB-A565-8E5CC24A10D3Q27023204-E2CA7CC0-D794-4981-8240-0082279DBFD9Q27027503-D6E9A22A-41DB-41D4-BD42-F89413C6C5B3
P2860
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
description
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique The Lancet
@fr
artículu científicu espublizáu en 2010
@ast
im Juli 2010 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 24 July 2010)
@en
wetenschappelijk artikel (gepubliceerd op 2010/07/24)
@nl
наукова стаття, опублікована в липні 2010
@uk
مقالة علمية (نشرت في 24-7-2010)
@ar
ശാസ്ത്രപ്രബന്ധം
@ml
name
Oral poly(ADP-ribose) polymera ...... ncer: a proof-of-concept trial
@ast
Oral poly(ADP-ribose) polymera ...... ncer: a proof-of-concept trial
@en
type
label
Oral poly(ADP-ribose) polymera ...... ncer: a proof-of-concept trial
@ast
Oral poly(ADP-ribose) polymera ...... ncer: a proof-of-concept trial
@en
prefLabel
Oral poly(ADP-ribose) polymera ...... ncer: a proof-of-concept trial
@ast
Oral poly(ADP-ribose) polymera ...... ncer: a proof-of-concept trial
@en
P2093
P3181
P1433
P1476
Oral poly(ADP-ribose) polymera ...... ncer: a proof-of-concept trial
@en
P2093
Bell-McGuinn KM
Carmichael J
Friedlander M
Matulonis U
P304
P3181
P356
10.1016/S0140-6736(10)60893-8
P407
P577
2010-07-24T00:00:00Z